926 results about "Single-domain antibody" patented technology

The invention discloses a camel source single-domain antibody GH12 for recognizing a conformation B cell epitope in clostridium difficile glutamate dehydrogenase and application of the camel source single-domain antibody GH12. The nucleotide sequence of the camel source single-domain antibody GH12 is shown as SEQ ID NO: 1, and the amino acid sequence of the camel source single-domain antibody GH12 is shown as SEQ ID NO: 2. The camel source single-domain antibody GH12 disclosed by the invention has the advantages of strong specificity, high sensitivity, good accuracy and the like, and it is proved that the camel source single-domain antibody GH12 can be used for detecting recombinant expressed CD-GDH and endogenous CD-GDH by enzyme-linked immunosorbent assay (ELISA), protein dot blot hybridization (DB) and other methods.

Provided are an anti-BCMA single-domain antibody, and a preparation method therefor and the use thereof. Specifically, provided is a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity, can thoroughly specifically target BCMA-positive cells, and can be applied to the detection of BCMA expression in bone marrow cells of MM patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating BCMA-target-related diseases (such as multiple myeloma, B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma and Hodgkin's lymphoma); or a BCMA protein detection kit, etc. The single-domain antibody has a stable structure, a small molecular size, is easily recombinantly expressed and has a low production cost, can be used alone or as a drug delivery system to carry relevant drugs, and has very wide prospects and important significance in fields such as drug application and clinical diagnosis.

The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

The present invention discloses a porcine Seneca virus neutralization liquid phase blocking ELISA kit, which comprises an effective amount of porcine Seneca virus antigen, an effective amount of porcine Seneca virus single domain antibody 1, an effective amount of porcine Seneca virus single domain antibody 2, and a matching detection reagent. The porcine Seneca virus antigen is porcine Seneca virus particles purified by sucrose density gradient centrifugation, and the particle size of the purified porcine Seneca virus particles is 20 to 30 nm. The amino acid sequence of the heavy chain variable region of the porcine Seneca virus single domain antibody 1 is shown in SEQ ID NO.1. The amino acid sequence of the heavy chain variable region of the porcine Seneca virus single domain antibody 2 is shown in SEQ ID NO.2. The kit of the present invention has the advantages of high efficiency, simplicity, sensitivity, stability, etc., has a good correlation with the traditional diagnostic method virus neutralization experiment, and is suitable for a wide range of applications.

The invention relates to the technical field of immunotherapy, and provides a GPRC5D-targeted single-domain antibody, a chimeric antigen receptor and application of the GPRC5D-targeted single-domain antibody and the chimeric antigen receptor. Specifically, the invention provides a GPRC5D-targeted single-domain antibody, a GPRC5D-targeted chimeric antigen receptor (CAR) constructed by using the single-domain antibody, and an engineered immune effector cell containing the CAR. The invention also provides a single-domain antibody targeting GPRC5D, a chimeric antigen receptor and an application of the engineered immune effector cell containing the CAR in preparation of drugs for diagnosis, prevention and / or treatment of diseases or symptoms related to GPRC5D expression.

Provided herein are single domain antibody / polymer fluorescent tandem dye conjugates. Aspects of the conjugates provided herein include single domain antibodies having one or more polymer tandem fluorescent dyes conjugated thereto. In some cases, a polymer tandem fluorescent dye includes: (i) a polymer backbone consisting of non-conjugated repeating units; (ii) a plurality of pendant donor chromophore groups, each group independently attached to a non-conjugated repeating unit of the polymer backbone; and (iii) one or more pendant acceptor fluorophores attached to non-conjugated repeating units of the polymer backbone wherein the pendant donor and acceptor fluorophores are in an energy transfer relationship. Also provided herein are methods of using the conjugates, for example, methods for assessing the presence of a target analyte in a sample, and kits comprising conjugates useful in embodiments of the methods.

Provided are single domain antibodies having binding specificity to the human GPRC5D protein. Such antibodies, as well as their multi-specific counterparts and chimeric antigen receptors are capable of targeting cancer cells expressing GPRC5D, and thus can be used to treat the cancer, in particular hematological cancers.

The invention belongs to the technical field of gene engineering, and particularly relates to a Cre reporting system based on single-domain antibody labeling and application of the Cre reporting system. According to the shark single-domain antibody with Cre specificity, when a DNA sequence of dLox-EGFP is provided, Cre can be marked and reported in real time, and reporter genes can be expressed only when Cre exists in cells, so that a strictly regulated gene expression platform is provided. The mark is completely reversible and is completely compatible with the currently used Cre / loxp system.

An anti-Nectin-4 single-domain antibody and the use thereof. Provided are a single-domain antibody specifically targeting Nectin-4, and amino acid sequences of a framework region FR and a complementarity-determining region CDR of a VHH chain thereof. The anti-Nectin-4 single-domain antibody can bind to a Nectin-4 antigen. An antibody-drug conjugate and a multi-specific antibody targeting the Nectin-4 target prepared by means of using the single-domain antibody have an excellent activity and high therapeutic efficacy.

The invention relates to an anti-PD-1 single-domain antibody and application thereof. The complementarity determining region of the VHH chain of the anti-PD-1 single-domain antibody comprises a CDR1 with an amino acid sequence as shown in SEQ ID NO.1, a CDR2 with an amino acid sequence as shown in SEQ ID NO.2 and a CDR3 with an amino acid sequence as shown in SEQ ID NO.3. The invention further discloses a preparation method of the anti-PD-1 single-domain antibody. The PD-1 protein is used for immunizing alpaca, an antibody display library is constructed, an antibody combined with the PD-1 protein is screened, the single-domain antibody with high specificity and affinity is obtained, and the single-domain antibody has the capacity of blocking combination of PD-1 and PD-L1 and the function of enhancing immune cells.

The invention provides a GPRC5D single-domain antibody B11, and the GPRC5D single-domain antibody B11 has relatively strong binding activity and reaction specificity on GPRC5D. The invention provides an amino acid sequence of a single-domain antibody, an antibody derivative, a biological material and application thereof. The single-domain antibody provided by the invention can be used for constructing a chimeric antigen receptor T cell, and the chimeric antigen receptor T cell has stronger killing power on a target cell.

The invention provides a CLDN6 single domain antibody and a humanization method thereof. The CLDN6 single-domain antibody provided by the invention has targeted specificity to CLDN6, only recognizes the CLDN6 and does not recognize CLDN3, CLDN4 and CLDN9 of the same family, or the recognition modes are obviously different. The CLDN6 single-domain antibody 1H07 with targeting specificity provided by the invention can be used for constructing a chimeric antigen receptor (CAR) and a bivalent antibody (bispecific antibody). The CAR constructed based on the antibody sequence can be transduced into a T cell to create a CAR-T cell specifically targeting CLDN6, and the CAR-T cell can be used for treating solid tumors such as ovarian cancer.

The present application provides a bispecific antibody comprising a first antigen binding fragment that binds to an HLA-A24 / PRAME complex and a second antigen binding fragment that binds to an activated T cell antigen, a single domain antibody that binds to an HLA-A24 / PRAME complex, a pharmaceutical composition comprising the bispecific antibody or the single domain antibody, and uses thereof.

The invention relates to the field of molecular imaging, in particular to a molecular probe targeting GPC3. The invention claims to protect a molecular probe targeting GPC3, the molecular probe is a compound having the following sequence, or a pharmaceutically acceptable salt or ester thereof: (GPC3 antibody, including antibody fragment of GPC3 antibody, or single domain antibody thereof) m-Rn, where R is selected from a linking group, a chelating agent, a radionuclide, another targeting polypeptide or monoclonal antibody, monoclonal antibody fragment, single domain antibody, and Rn is selected from a linking group, a chelating agent, a radionuclide, another targeting polypeptide or monoclonal antibody, a monoclonal antibody fragment, and a single domain antibody. And a group consisting of small molecule inhibitors; wherein n represents the number of R, and n is equal to 0-4; wherein m is not 0. The probe has good in-vitro stability, can be clearly developed in tumors, and has good specificity.

The present invention relates to the field of molecular imaging, nuclear medicine and single-domain antibody technology for tumor diagnosis and treatment, and in particular to a method for preparing a radionuclide-labeled Trop2-specific single-domain antibody probe and its application. The Trop2-specific single-domain antibody has a CDR1 having an amino acid sequence shown in SEQ ID No.1, a CDR2 having an amino acid sequence shown in SEQ ID No.2, and a CDR3 having an amino acid sequence shown in SEQ ID No.3. The Trop2-specific single-domain antibody prepared by the present invention 18 The F-labeled single-domain antibody probe is used for immuno-PET imaging, which realizes the non-invasive visualization of Trop2 in vivo and further realizes the non-invasive diagnosis of Trop2-positive tumors. The probe has the advantages of simple preparation process, low cost, high specificity, high stability, short imaging cycle, low radiation dose, and easy clinical transformation.

The present disclosure provides, among other things, single domain antibodies that bind to human serum albumin. Pharmaceutical compositions comprising the single domain antibodies disclosed herein are provided.

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL10Ra, compositions comprising such antibodies, and methods of use thereof.

This invention discloses a camel-derived CRP single-domain antibody, its preparation method, and its applications, relating to the biomedical field. The method involves enriching CRP antigen in alpaca leukocytes immunized with the antigen, followed by single-cell screening and sequencing. Through sequencing structural analysis, a recombinant plasmid of the camel-derived CRP antibody is constructed. This plasmid is cloned and transformed into eukaryotic cells to express related antibodies. Monoclonal antibodies with human CRP resistance are screened for expression. The VHH domain of the monoclonal antibody is cloned and expressed, and paired screening yields CRP-VHH monoclonal antibodies with antibody activity. This antibody can be used in ELISA kits, chemiluminescence kits, and latex kits, possessing the same functionality as existing kits. Furthermore, this antibody also has applications in the preparation of antitumor drugs.

Provided are single domain anti-4-1BB antibodies and polypeptides, such as bispecific antibodies and chimeric antigen receptors, that include these single domain antibodies. Methods of using the antibodies or polypeptides for treating and diagnosing diseases such as cancer are also provided.

An anti-human TNFR2 antibody or antigen-binding fragment thereof and uses and pharmaceutical compositions thereof. The anti-human TNFR2 antibody or antigen-binding fragment thereof is capable of specifically binding to TNFR2, inhibiting Treg cell proliferation, and / or promoting effector Teff cell proliferation and activation.

The invention provides an antibody for specifically targeting GPRC5D, an application of the antibody, and a single-domain antibody F08 for specifically targeting GPRC5D, wherein the binding activity and the reaction specificity of the single-domain antibody F08 for the GPRC5D are relatively high. The invention also provides nucleic acid molecules encoding the single domain antibodies, vectors and recombinant host cells, as well as methods of producing the single domain antibodies and antibody derivatives. The single-domain antibody provided by the invention can be used for constructing a chimeric antigen receptor T cell, and the chimeric antigen receptor T cell has stronger killing power on a target cell.

The present application provides a bispecific antibody comprising a first antigen binding fragment that binds to an HLA-A02 / MAGE-A4 complex and / or an HLA-A02 / MAGE-A8 complex and a second antigen binding fragment that binds to an activated T cell antigen, a single domain antibody that binds to an HLA-A02 / MAGE-A4 complex and / or an HLA-A02 / MAGE-A8 complex, and a method for preparing the same. The invention also relates to a pharmaceutical composition containing the bispecific antibody or the single-domain antibody and application of the bispecific antibody or the single-domain antibody.

Provided are complementarity determining regions (CDRs) of the VHH chain of an anti-PD-L1 single domain antibody, wherein the CDRs of the VHH chain comprise the following: CDR1 having the amino acid sequence set forth in SEQ ID NO:5n+1; CDR2 having the amino acid sequence set forth in SEQ ID NO:5n+2, or a CDR2 having an amino acid sequence which has greater than 85% sequence identity to the sequence set forth in SEQ ID NO:2; and CDR3 having the amino acid sequence set forth in SEQ ID NO:5n+3, where each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

The application belongs to the technical field of biological medicine and immunology, and particularly relates to a single-domain antibody targeting cross binding of human and cynomolgus monkey CD46 and application thereof. The application utilizes alpaca to generate nanoscale antibodies, the molecular weight of which is about 15 kDa, and the nanoscale antibodies can more efficiently penetrate solid tumor tissues or cross blood-brain barrier, and the binding efficiency of the antibodies and target points is as high as possible. The 11 single-domain antibodies prepared by the application have specificity of anti-human and anti-cynomolgus monkey CD46, and in the binding detection with CD46 target proteins and CD46 overexpression cells, the binding efficiency is significantly better than that of Anti-CD46 humanization antibody, and the single-domain antibodies can be used for tumor treatment. Meanwhile, the single-domain antibodies have cross binding ability of cross species, and can be directly used for preclinical pharmacodynamics and safety evaluation, without the need of developing species-specific alternative antibodies, so that the application achieves 'one target and double effect'.

The technology relates in part to methods for activating and expanding multi-subsets of gamma delta T cells. In some aspects, the technology relates to multi-subsets of gamma delta T cells. In some aspects, the technology relates to activated and expanded multi-subsets of gamma delta T cells produced by methods described herein. In some aspects, the multi-subsets of gamma delta T cells are modified. In some aspects, the multi-subsets of gamma delta T cells comprise one or more chimeric antigen receptors. In some aspects, the chimeric antigen receptors comprise one or more antigen binding domains with binding specificity to TROP2 and / or PD-L1. In some aspects, the multi-subsets of gamma delta T cells express IL-15. In some aspects, the multi-subsets of gamma delta T cells comprise one or more genome modifications. In some aspects, the multi-subsets of gamma delta T cells comprise a TGFβR2 knock-out. The technology also relates in part to single-domain antibodies (nanobodies) that target TROP2, PD-L1, or TROP2 and PD-L1, uses for immune cell engineering, pharmaceutical compositions thereof, diagnostic and non-diagnostic reagents thereof, and therapeutic and non-therapeutic methods of use thereof.

Provided are a therapeutic anti-IGF-1R and anti-TSHR bispecific antibody and a use thereof. Specifically disclosed are a single-domain antibody against IGF-1R, a bispecific antibody against IGF-1R and TSHR, a nucleic acid encoding the single-domain antibody or the bispecific antibody, a vector comprising the nucleic acid, and a host cell comprising the nucleic acid or the vector. Also provided are a pharmaceutical composition and conjugate or immune fusion comprising the antibody, and a treatment method using the antibody.

The invention provides a preparation method of DC cells. The preparation method is especially suitable for rapidly obtaining high-purity and high-functional-activity DC cells. The method comprises the steps of separation from peripheral blood mononuclear cells (PBMC), induction culture, maturation treatment and the like, maturation of the dendritic cells is promoted by introducing an anti-CD47 single-domain antibody or LPS, and the immunocompetence of the dendritic cells is remarkably improved. The method is further applied to preparation of an anti-tumor cell preparation, the capability of activating tumor specific T cells by tumor antigen-loaded DC cells can be remarkably enhanced, and the killing activity of the T cells to tumor cells is improved. The preparation method provided by the invention overcomes the defects in the prior art, has the advantages of high efficiency, safety and stability, and can provide a more reliable cell therapy scheme for tumor immunotherapy.

The present disclosure provides an anti-IL13RA2 single domain antibody (e.g., a VHH domain antibody), and a chimeric antigen receptor (CAR) that binds IL13RA2, the chimeric antigen receptor comprising: the anti-IL13RA2 single domain antibody in an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Immune effector cells transduced with the disclosed CAR constructs can be used in cancer immunotherapy.

The present invention relates to an antibody or an antigen-binding fragment thereof comprising a single domain antibody specifically binding to mesothelin, an antibody conjugate comprising same, a pharmaceutical composition for preventing or treating cancer or a tumor, and a composition for diagnosing or monitoring cancer or a tumor. When the antibody or composition comprising same is used, mesothelin-related cancer or tumors can be effectively prevented, treated, or diagnosed.

The invention discloses a coupling drug of albumin binding peptide fused with a single-domain antibody and a preparation method and application thereof, and relates to the technical field of biological pharmacy, the coupling drug is obtained by fusing albumin binding peptide and the single-domain antibody to obtain fusion protein and coupling drug molecules with the fusion protein; the fusion form of the albumin binding peptide and the single-domain antibody comprises a single-target monoclonal antibody mode: the C terminal or the N terminal of the albumin binding peptide is fused with one single-domain antibody; in the single-target double-antibody mode, the C end and the N end of the albumin binding peptide are simultaneously fused with one single-domain antibody or are respectively fused with two same single-domain antibodies; and a double-target double-antibody mode: the C end and the N end of the albumin binding peptide are respectively fused with two different single-domain antibodies. By means of the characteristic of high-affinity binding of the albumin binding peptide and the serum albumin, the long-acting effect of the coupling medicine in vivo can be achieved, the effect that the coupling medicine is enriched to a tumor part in vivo in a targeted mode can be achieved, and the anti-tumor purpose is achieved.